{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T22:37:32Z","timestamp":1791067052810,"version":"4.1.0"},"reference-count":41,"publisher":"Wiley","license":[{"start":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T00:00:00Z","timestamp":1787616000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T00:00:00Z","timestamp":1787616000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Epileptic Disorders"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Current recommendations for prescribing combined oral contraceptives (COCs) to people with epilepsy are often conflicting, particularly for weak inducers of cytochrome P450 3A4. We aimed to critically review the literature and compare the antiseizure medication (ASM)\u2010induced changes in exposure to COC components.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this systematic review and network meta\u2010analysis (PROSPERO: CRD42024513792), in accordance with PRISMA 2015\/2020, we searched PubMed, EMBASE, Cochrane, and FDA documents up to January 2026. Eligible studies were clinical trials assessing induction (\u2265\u20095\u2009days) of ethinylestradiol combined with progestins by ASMs. The areas under the concentration\u2010time curve (AUC) of individual hormones with\/without the ASM were indirectly compared. The point estimate was the standardized mean difference (SMD; significant when the 95% confidence interval does not encompass zero). Bias risk was assessed using the PKclin tool.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The 17 studies (16 reports) involving 399 individuals and 15 ASMs were all conducted with COCs containing the two progestins least sensitive to enzyme induction and \u2265\u200930\u2009\u03bcg ethinylestradiol. Nine ASMs were studied at doses 13\u201375% lower than the recommended maximum (median 50%). Brivaracetam (100\u2009mg\/day) reduced the exposure to ethinylestradiol more than 1000\u2009mg\/day levetiracetam (SMD \u201010; 95% confidence interval\u2009\u2212\u20090.20\u20100). The effects of 300\u2009mg\/day lamotrigine on ethinylestradiol and levonorgestrel were greater than those of 400\u2009mg\/day lacosamide (0.18; 0.11\u20130.25, 0.28; 0.20\u20130.37). Low\u2010dose (50\u2009mg\/day) and high\u2010dose (200\u2009mg\/day) topiramate were comparable in their effects on ethinylestradiol and norethindrone, and the low dose did not differ from weak inducers in altering ethinylestradiol exposure.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance<\/jats:title>\n                    <jats:p>Current recommendations may underestimate ASM effects on exposure to COC components, especially those in newer COCs. Greater caution is recommended with low\u2010dose topiramate. For individuals treated with weak COC inducers without additional contraceptive means, COCs containing levonorgestrel or norethindrone might be preferable given their lower vulnerability to induction.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/epd2.70373","type":"journal-article","created":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T13:50:37Z","timestamp":1787665837000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The effect of antiseizure medications on the exposure to combined oral contraceptives: A systematic review and network meta\u2010analysis"],"prefix":"10.1002","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-0461-4272","authenticated-orcid":false,"given":"Hagar","family":"Cohen","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacy School of Pharmacy, Faculty of Medicine, the Hebrew University of Jerusalem  Jerusalem Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-7674-3820","authenticated-orcid":false,"given":"Amnah Omar","family":"Mahajna","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy School of Pharmacy, Faculty of Medicine, the Hebrew University of Jerusalem  Jerusalem Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0415-566X","authenticated-orcid":false,"given":"Tomer","family":"Ben\u2010Shushan","sequence":"additional","affiliation":[{"name":"Medical Library Authority, the Hebrew University of Jerusalem  Jerusalem Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1559-9258","authenticated-orcid":false,"given":"Ilan","family":"Matok","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy School of Pharmacy, Faculty of Medicine, the Hebrew University of Jerusalem  Jerusalem Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6507-3532","authenticated-orcid":false,"given":"Sara","family":"Eyal","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy School of Pharmacy, Faculty of Medicine, the Hebrew University of Jerusalem  Jerusalem Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,8,25]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1979.tb04834.x"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1097\/EDE.0000000000001302"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/epd2.70205"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/epi.70202"},{"key":"e_1_2_11_6_1","unstructured":"FDA. USA Food and Drug Administration.Topamax (topiramate).https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2026\/020505s068lbl.pdf"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/0009-9236(95)90172-8"},{"key":"e_1_2_11_8_1","unstructured":"FDA. USA Food and Drug Administration.Felbatol (felbamate).https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/020189s027lbl.pdf"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2602"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1848"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/cts.12499"},{"key":"e_1_2_11_12_1","unstructured":"FDA.Clinical Drug Interaction Studies With Combined Oral Contraceptives Guidance for Industry.https:\/\/www.fda.gov\/media\/143849\/download"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.7326\/M14-2385"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n160"},{"key":"e_1_2_11_15_1","volume-title":"Antiepileptic Drug Interactions: A Clinical Guide","author":"Patsalos P","year":"2022"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.119.087270"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/epd2.70232"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13643-016-0384-4"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/epi.17822"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-015-0236-8"},{"key":"e_1_2_11_21_1","unstructured":"FDA. Center for Drug Evaluation and Research.Fycompa (perampanel). Application number: 202834.2011Clinical Pharmacology and Biopharmaceutics Review(s).https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2012\/202834Orig1s000ClinPharmR.pdf"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2008.01665.x"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1080\/17425255.2020.1724956"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/epi.12085"},{"key":"e_1_2_11_25_1","unstructured":"FDA.Clinical drug interaction studies with combined Oral contraceptives. Guidance for Industry.https:\/\/www.fda.gov\/media\/143849\/download2023."},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.seizure.2015.03.006"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.2165\/00023210-200519030-00003"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1999.tb00779.x"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200443120-00001"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1528-1157.2003.55602.x"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1997.tb01123.x"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.1097\/AOG.0000000000004697"},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2005.02539.x"},{"key":"e_1_2_11_34_1","unstructured":"FDA. USA Food and Drug Administration.Lamictal (lamotrigine).https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/020241s068s069 020764s061s062 022251s032s033lbl.pdf"},{"key":"e_1_2_11_35_1","doi-asserted-by":"publisher","DOI":"10.1177\/15357597241258514"},{"key":"e_1_2_11_36_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.25031"},{"key":"e_1_2_11_37_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-53813-1"},{"key":"e_1_2_11_38_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000209175"},{"key":"e_1_2_11_39_1","unstructured":"FDA.For Healthcare Professionals | FDA's Examples of Drugs that Interact with CYP Enzymes and Transporter Systems.https:\/\/www.fda.gov\/drugs\/drug\u2010interactions\u2010labeling\/healthcare\u2010professionals\u2010fdas\u2010examples\u2010drugs\u2010interact\u2010cyp\u2010enzymes\u2010and\u2010transporter\u2010systems"},{"key":"e_1_2_11_40_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200746020-00003"},{"key":"e_1_2_11_41_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-024-01426-8"},{"key":"e_1_2_11_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.xphs.2020.10.027"}],"container-title":["Epileptic Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/epd2.70373","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/epd2.70373","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/epd2.70373","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T13:50:38Z","timestamp":1787665838000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/epd2.70373"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,25]]},"references-count":41,"alternative-id":["10.1002\/epd2.70373"],"URL":"https:\/\/doi.org\/10.1002\/epd2.70373","archive":["Portico"],"relation":{},"ISSN":["1294-9361","1950-6945"],"issn-type":[{"value":"1294-9361","type":"print"},{"value":"1950-6945","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,25]]},"assertion":[{"value":"2026-04-28","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-03","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-25","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"epd2.70373"}}